Ascendis Pharma A/S American Depositary Shares (ASND) fair value

ACCE thesis

Ascendis Pharma sells TransCon-based long-acting therapies, most notably YORVIPATH (palopegteriparatide) for hypoparathyroidism and SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency, with the company's revenue now driven by these launched products. The structural case rests on its drug-delivery platform, which lets a daily injectable become a once-weekly or once-monthly dose, a convenience edge that matters in pediatric and chronic endocrine markets with entrenched incumbents. Revenue growth of 114.7% and a 65.0% operating margin show the launches converting into profit faster than most mid-cap biotechs manage, and the 91.3% gross margin reflects how little of each sale goes to cost of goods. At 17.4 times trailing earnings and 19.8 times forward, the stock is not priced like a speculative biotech, though the multiple is only as durable as the launch trajectory and reimbursement uptake that the next few quarters will reveal. The name is worth a deeper look mainly to test whether that growth rate holds once the initial patient cohorts are exhausted, and to weigh it against competitive pressure from other long-acting growth hormone and parathyroid hormone programs.